In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

在慢病管理不断前移的背景下，如何在疑似心衰阶段实现更早识别和干预，成为临床关注的重要问题。近日，国际心血管领域权威期刊《欧洲心脏杂志》（European Heart Jouranl, EHJ）发表的一项大规模真实世界研究显示，在社区疑似心衰人群中，若NT-proBNP水平升高后 ...

Oxford, UK - The "first large-scale international analysis" of the diagnostic value of N-terminal brain-type natriuretic peptide (NT-proBNP) in the setting of suspected acute HF has identified ...

NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis of the condition in primary care, an expert report has said. The Alliance ...

A discussion on the link between LVEF, nT-proBNP, and cardiac remodeling in predicting disease progression. Scott D. Solomon, MD: It’s important to remember that ejection fraction and natriuretic ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most significant is ...

Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...

At this year's congress of the American Heart Association (AHA) in Chicago, November 13-17, new data on the use of NT-proBNP to guide heart failure therapy was presented by study investigators from ...

Gentian Diagnostics ASA ( (DE:6FK)) has issued an announcement. Gentian Diagnostics ASA reports continued solid progress in developing its turbidimetric NT-proBNP assay, its top pipeline project, with ...